IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001)[1].
Target-Kategorie:
NTPDase
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten